Royalty Report: Drugs, Biotechnology, Therapeutic – Collection: 6777


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Biotechnology
  • Therapeutic
  • Cancer
  • Antibody
  • Disease
  • Drug Discovery
  • Immune
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6777

License Grant
The parties desire to enter into a definitive agreement to collaborate to produce fully human monoclonal antibodies to certain antigen targets in order to develop and commercialize genomics-derived, antibody-based products on the terms set forth below.  The Parties have entered into this collaboration to jointly research, develop and commercialize Collaboration Products with respect to Collaboration Targets throughout the Territory as set forth in this Agreement.
License Property
Collaboration Product shall mean any Antibody Product that contains a Collaboration Antibody.
Field of Use
The rights granted apply for the diagnosis, prophylaxis or treatment of human diseases or conditions.

IPSCIO Record ID: 6823

License Grant
Utilizing the grant we, the Australian Licensee,  received from the Commonwealth Government of Australia under the Biotechnology Innovation Fund, or BIF, we entered into an agreement to undertake proof of concept research for our prospective Alzheimer’s disease vaccine target.  This collaboration enabled us to access Licensor’s adjuvant vaccine technology, known as DCtag, in the design of candidate vaccine fragments.
License Property
Under the terms of our contractual relationship, we retained all intellectual property rights to our monoclonal antibodies that were used for the collaboration.

IPSCIO Record ID: 237254

License Grant
The Collaboration agreement is to jointly research, develop and commercialize Collaboration Products with respect to Collaboration Targets throughout the Territory.

Pursuant to the Unilateral Development and Commercialization agreement, Licensor grants with respect to each Unilateral Product, an exclusive, even as to Licensor and its Affiliates, worldwide right and license, with the right to sublicense, under the Licensor Technology, the Collaboration Technology and the Joint Technology to Exploit such Unilateral Products in the Territory.

License Property
A Unilateral Product is from the research, development and commercialization of all Collaboration Antibodies and Collaboration Products to the applicable Collaboration Target.

The Collaboration is for the jointly research, develop and commercialize human antibodies against Licensee cancer targets.

Field of Use
Licensee is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer.

IPSCIO Record ID: 28868

License Grant
The Irish Licensor hereby grants to the Company a worldwide, non-exclusive, non-transferable license, without any right to sublicense, under the Irish Licensor's Patent Rights and Know-How to
(a) make or have made Licensed Antibody Phage Display Materials;
(b) solely for Research and Development purposes, conduct Antibody Phage Display;
(c) make or have made Research Quantities of a Licensed Immunoglobulin;
(d) transfer Antibody Phage Display Materials;
(e) transfer Research Quantities of a Licensed Immunoglobulin or Licensed Immunoglobulin Information to a Company Collaborator or a Development Partner of the Company;
(f) sell, offer to sell, import and export Licensed Immunoglobulins;
(g) use Licensed Immunoglobulins; and
(h) use, offer for sale, sell, import and export Products for use in the treatment, prophylaxis, diagnosis or monitoring of a human disease state or condition.

The Company is willing to grant the Irish Licensor non-exclusive licenses, in order to permit the Irish Licensor to engage in certain research, development and commercial activities.

License Property
The Company's patented phage display technology rapidly selects antibodies, peptides and small proteins that bind with high affinity and specificity to therapeutic targets.

Licensed antibody phage display materials means any collection or library of polynucleotide sequences which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or any collection or library of bacteriophage wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin or at least a functionally operating region of an antibody variable region and an outer surface polypeptide of a bacteriophage.

IPSCIO Record ID: 1395

License Grant
Licensor hereby grants, and Licensee hereby accepts, the following licenses

(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.

License Property
Licensor has developed a murine monoclonal antibody directed against the CCR5 antigen and designated by Licensee's as “PRO 140”

“Humanized Antibody(ies)” means the humanized form of the Murine Antibody.

“Licensed Product(s)” means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.

“Murine Antibody(ies)” means, subject to Section 2.01(b), the murine monoclonal antibody designated as “PRO 140” directed against the Target Antigen.

Field of Use
Licensee shall also evaluate the Humanized Antibody to determine whether such antibody also possesses anti-HIV activity not less than one-third (1/3) that of the Murine Antibody (“Minimum Anti-HIV Activity”) as measured according to an HIV-1 infectivity assay that measures the extent of HIV-l replication.

IPSCIO Record ID: 222549

License Grant
For the research license, Licensor grants a non-exclusive, non-transferable license, under the Licensor Technology to immunize the Mice to make Antibodies against such Antigen, and to further evaluate the Antibodies generated during the Evaluation Period.

For the commercial license,  Licensor grant the following licenses, on an Licensee Target-by-Licensee Target basis
– a worldwide, exclusive, non-transferable license, with the right to grant a sublicense to its Affiliates, under the Licensor Technology to immunize the Mice to make Antibodies against such Licensee Target, and
– a worldwide exclusive license under the Licensor Technology, with the right to sublicense, to make, have made, import, have imported, use, offer for sale and sell Products containing Antibodies against such Licensor Target.

Licensee shall have no right to grant sublicenses to use the Mice, but may grant sublicenses under
the Licensee Technology to the extent necessary to develop, make, have made, import, use, offer for
sale and sell Products.

License Property
Licensor is the sole and exclusive owner of certain transgenic_ Mice (as defined below) useful for the preparation of fully human monoclonal antibodies;

Licensor Technology includes the Confidential Information and Mice, and patent rights which claims an invention which is necessary for the use of the Mice to prepare the Antibodies or to develop, produce, make, have made, import, have imported, use, offer for sale and sell the Antibodies.

The Product shall mean any composition or formulation comprising one or more Antibodies, or a portion thereof, for the diagnosis, prophylaxis or treatment of human disease.

Licensee Target shall mean an Antigen selected by Licensee for immunization of Licensors HuMAb mice to generate human antibodies directed against an Antigen, in each case, which Licensor has informed Licensee is available for licensing.

HuMAb -Mouse technology is a transgenic mouse system that creates high affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.

Field of Use
Licensee desires to use the Mice to evaluate their utility for the development of fully human monoclonal antibodies against specific antigens.

Incorporating this technology into Licensee's broad drug discovery program will significantly enhance Licensee continuing efforts to identify new drug candidates.

IPSCIO Record ID: 2946

License Grant
Pursuant to the terms of the Collaboration Agreement, the Company and Parent each granted the other certain intellectual property Licenses and product rights on a worldwide basis in order to enable the parties to collaborate in research and development of certain antibody-based product candidates for the treatment of cancer and other diseases, and, in the event that further development work is successful, to commercialize any resulting products.

The collaboration includes a grant by the Company to Parent of a worldwide License to commercialize ipilimumab, a fully human antibody product developed using the Company’s UltiMAb® technology, that is antagonistic to cytotoxic T-lymphocyte antigen 4 (CTLA-4). The collaboration further includes a grant by the Company to Parent of a License to commercialize MDX-1379 subject to the terms of the License granted by the United States Public Health Service to the Company on May 6, 2003. Under the Collaboration Agreement, Parent is required to pay upfront fees, regulatory milestone payments and royalties.

License Property
UltiMAb Human Antibody Development System – our solution to making antibodies with fully human protein sequences is to use transgenic strains of mice in which mouse antibody gene expression is suppressed and effectively replaced with human antibody gene expression. Our human antibody technology includes (i) our HuMAb-Mouse technology, (ii) Kirin's TC Mouse technology, and (iii) the KM-Mouse technology, a crossbred mouse that combines the characteristics of our HuMAb-Mouse with Kirin's TC Mouse. In total these technologies constitute our UltiMAb Human Antibody Development System, and we believe they offer the broadest and most powerful set of human antibody technologies in the industry.

Parent is responsible for 65% of all development costs related to clinical trials intended to support regulatory approval in both the United States and the European Union, with the remaining 35% to be paid by the Company. The parties share equally the costs of any clinical trials of products intended solely for regulatory approval in the United States, and Parent is fully responsible for all development efforts that relate solely to regulatory approval in the European Union and other parts of the world.

Field of Use
MDX-1379 is used for patients with previouslytreated, unresectable Stage III or IV melanoma.

IPSCIO Record ID: 7769

License Grant
This Agreement is to sell certain rights, title, and interest in certain antigen targets pertaining to its fully human monoclonal antibodies to an undisclosed third party.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 233496

License Grant
Pursuant to this agreement, the Licensee has the right to grant sub-licenses to Licensees product.  The Licensee may grant a Sublicense with respect to any Licensee Product for use in the Therapeutic Field, and, the Diagnostic Field.

During the Research term of this agreement, Licensee shall not make any other grant to the related antigens.

License Property
Licensee Product shall mean, with respect to any Licensee Licensed Antigen, any product comprising an Antibody which binds to such Licensee Licensed Antigen, or Genetic Material that encodes such an Antibody wherein, in respect of each Licensee Product, said Genetic Material does not encode multiple antibodies.

Antigens shall mean, collectively, the Research Antigens, Eligible Antigens, Optioned Antigens and Licensed Antigens, and Antigen shall mean any one of the Antigens.

Research Antigens shall mean, collectively, the antigens which are selected by the Collaboration, Licensor or Licensee for use in the Research Program, for which Licensor and Licensee have the right to grant the other party the commercial license, and which are not Optioned Antigens or Licensed Antigens, and Research Antigen shall mean any one of the Research Antigens.

Field of Use
The Commercial Field shall mean, collectively, the Therapeutic Field and the Diagnostic Field.

The Diagnostic Field shall mean the use of Products for the following human medical purposes the detection, diagnosis and monitoring of any disease, predisposition, state or condition in humans or the selection of a particular patient(s) to receive a particular therapeutic treatment(s).

The Therapeutic Field shall mean the use of Products for the following human medical purposes the prevention or treatment of any disease, state or condition in humans.

The goal of the five-year alliance is to develop antibody therapeutics against promising antibody drug targets in the human genome. The candidates are intended to treat a broad range of diseases, including metabolic diseases, cancer, inflammation, and autoimmune disorders.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.